Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s portfolio: Firdapse for Lambert-Eaton myasthenic syndrome, Agamree ...
May 7, 2026 06:40 AM EDTUpdated 08:39 AM DealsPharma Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst Ayisha Sharma News Reporter Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that